S'abonner

Involvement of Orai1 Ca2+ channel in the pathogenesis of pulmonary arterial hypertension. Orai1 as a new potential therapeutic target? - 09/03/22

Doi : 10.1016/j.rmr.2022.02.023 
B. Masson 1, 2, , H. Le Ribeuz 1, 2, J. Sabourin 3, E. Woodhouse 4, R. Foster 4, Y. Ruchon 1, 2, M. Dutheil 1, 2, A. Boët 1, 2, M.-R. Ghigna 1, 2, O. Mercier 5, D. Beech 4, J.-P. Benitah 3, M. Bailey 5, M. Humbert 1, 2, D. Montani 1, 2, V. Capuano 1, 2, F. Antigny 1, 2
1 Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France 
2 Inserm UMR S 999 «Hypertension pulmonaire: Physiopathologie et Innovation Thérapeutique», Hôpital Marie Lannelongue, Le Plessis-Robinson, France 
3 Inserm, UMR-S 1180, Signalisation et Physiopathologie Cardiovasculaire, Université Paris-Saclay, Châtenay-Malabry, France 
4 Leeds Institute of Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds, United Kingdom 
5 Service de Chirurgie Thoracique, Vasculaire et Transplantation Cardio-Pulmonaire, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Le Plessis Robinson, France 

Corresponding author.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Résumé

Background

The pathobiology of pulmonary arterial hypertension (PAH) involves pulmonary arterial smooth muscle cells (PASMCs) dysfunction leading to abnormal proliferation, apoptosis resistance and vasoconstriction. Store-operated Ca2+ entry (SOCE) strongly contributes to Ca2+ homeostasis in PASMCs, however, the role of SOCE archetype Orai1 Ca2+ channel in PAH pathogenesis was unclear.

Methods

To understand the role of Orai1, we used a combination of Ca2+ imaging, molecular biology, in vitro, ex vivo and in vivo approaches. We also analyzed the consequence of in vivo pharmacological inhibition of Orai1 in two experimental PH models.

Results

We demonstrated that SOCE is increased in human PASMCs from patients with idiopathic PAH (iPAH). Pharmacological inhibition of Orai1 or Orai1 knockdown by siRNA reduced SOCE as well as aberrant proliferation, apoptosis resistance phenotype, exacerbated cell migration and exacerbated calcineurin activity in iPAH-PASMCs. We showed that pharmacological inhibition of Orai1 reduced the capacity of isolated human pulmonary arteries to constrict. In PH rat models induced by Monocrotaline (MCT) or Chronic-Hypoxia (CH) exposure, we found an overexpression of Orai1 in lung and isolated pulmonary arteries. Finally, we found that the in vivo pharmacological inhibition of Orai1 by three different blockers reduced experimental-PH (MCT and CH).

Conclusion

Altogether our results provide proof of concept that Orai1 should be considered as a new therapeutic target in PAH.

Le texte complet de cet article est disponible en PDF.

Keyword : Circulation


Plan


© 2022  Publié par Elsevier Masson SAS.
Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 39 - N° 2

P. 117-118 - février 2022 Retour au numéro
Article précédent Article précédent
  • Beneficial effects of a preventive treatment with anethole trithione on pulmonary hypertension
  • L. Roubenne, M. Laisné, M. Campagnac, R. Marthan, B. Le Grand, C. Guibert
| Article suivant Article suivant
  • Endothelial P2X7 promotes venous thromboembolism
  • E. Olliver, V. Gourdou-Latyszenok, F. Couturaud, C. Lemarie